Get started
Author

Maxime Barakat

Observed names: Barakat, Maxime, M. Barakat, MAXIME BARAKAT
ORCID: 0000-0002-3000-2125
Observed ORCID: 0000-0002-3000-2125
OpenAlex ID: A5063525656
Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach
2013 · Roger S. McIntyre, Marie-Josée Filteau, et al. · Journal of Affective Disorders · 442
Extended‐release naltrexone/bupropion and liver health: Pooled, post hoc analysis from four randomized controlled trials
2020 · Harpreet S. Bajaj, Melonie Burrows, et al. · Diabetes Obesity and Metabolism · 28
The relationship between early weight loss and weight loss maintenance with naltrexone-bupropion therapy
2022 · Carel W. le Roux, Nadège Fils-Aimé, et al. · EClinicalMedicine · 27
PDF
Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors
2020 · Jensen Yeung, Ron Vender, et al. · Journal of the American Academy of Dermatology · 25
PDF
Psychiatric Safety and Weight Loss Efficacy of Naltrexone/bupropion as Add-on to Antidepressant Therapy in Patients with Obesity or Overweight
2021 · Roger S. McIntyre, Emilia Paron, et al. · Journal of Affective Disorders · 24
PDF
Ribavirin Aerosol in the Treatment of SARS-CoV-2: A Case Series
2021 · Emanuela Messina, Anna Danise, et al. · Infectious Diseases and Therapy · 22
PDF
Ribavirin aerosol in hospitalized adults with respiratory distress and COVID ‐19: An open‐label trial
2022 · Garyfallia Poulakou, Maxime Barakat, et al. · Clinical and Translational Science · 14
PDF
Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial
2021 · Sean Wharton, Peter Yin, et al. · International Journal of Obesity · 14
PDF
Efficacy of brodalumab in moderate-to-severe plaque psoriasis after failure of previous biologic therapy: A phase 4, multicenter, open-label study
2024 · Kim Papp, Vimal H. Prajapati, et al. · Journal of the American Academy of Dermatology · 11
PDF
Characterization of the effect of naltrexone/bupropion on body composition
2025 · Vanessa Tardio, Peter Yin, et al. · Diabetes Obesity and Metabolism · 8
PDF
Improving implementation of best practices in obesity management: Physician experiences in obesity care
2023 · Dayna Lee‐Baggley, Nadège Fils‐Aimé, et al. · Clinical Obesity · 8
A randomized, placebo‐controlled study to evaluate safety and pharmacokinetics of inhaled ribavirin
2022 · Peter Couroux, Alexandre Brkovic, et al. · Clinical and Translational Science · 7
Clinical Performance of Samfilcon A Contact Lenses in Intensive Digital Device Users: A Multicenter, Prospective Clinical Study
2021 · Ömür Ö. Uçakhan, Emrullah Taşındı, et al. · Ophthalmology and Therapy · 6
PDF
The i-ACT™ in Obesity educational intervention: a pilot study on improving Canadian family physician care in obesity medicine
2022 · Sean Wharton, David Macklin, et al. · BMC Family Practice · 3
PDF
A Review of Post-Inflammatory Pigmentation Changes: Pathophysiology, Diagnosis and Treatment
2026 · Geeta Yadav, Maxwell Sauder, et al. · Journal of Cutaneous Medicine and Surgery · 2
Clinico-Virological Outcomes and Mutational Profile of SARS-CoV-2 in Adults Treated with Ribavirin Aerosol for COVID-19 Pneumonia
2024 · Emanuela Messina, Giulia Morsica, et al. · Microorganisms · 2
Regional variability in Canadian routine care of type 2 diabetes, hypercholesterolemia, and hypertension: Results from the The Cardio-Vascular and metabolic treatments in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry
2020 · Ronald Goldenberg, Alan Bell, et al. · Journal of Cardiology · 2
P.749 Combination extended-release Naltrexone/Bupropion causes significant weight loss without worsening psychiatric symptoms: pooled analysis from the contrave obesity research program
2019 · J. Blavignac, R. McIntyre S., et al. · European Neuropsychopharmacology · 2
Brodalumab for Plaque Psoriasis in the Canadian Real-World Setting: A Retrospective Cohort Analysis of up to 4 Years
2025 · Veronique Gaudet, Irina Turchin, et al. · Dermatology and Therapy · 1
Real-world treatment outcomes with halobetasol propionate 0.01%/tazarotene 0.045% lotion in patients with mild-to-moderate plaque psoriasis: A Canadian multicenter retrospective chart review
2022 · Ronald Vender, Irina Turchin, et al. · JAAD International · 1
The Cardio-Vascular and Metabolic Treatments in Canada: Assessment of Real-Life Therapeutic Value Registry (CV-CARE): Registry Description and Baseline Patient Demographics
2020 · Ronald Goldenberg, Willoon Cheng, et al. · Journal of Hypertension and Management · 1
PDF
Real-world effectiveness of treatments for type 2 diabetes, hypercholesterolemia, and hypertension in Canadian routine care – Results from the CardioVascular and metabolic treatment in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry, 12-months results
2020 · Ronald Goldenberg, Alan Bell, et al. · Diabetes Research and Clinical Practice · 1
Clinical Implications of Interleukin-17 as a Hepato-Dermal Link in Patients With Psoriasis and Concomitant Steatotic Liver Disease
2026 · Elaine C. Dupuis, Patrick Fleming, et al. · Journal of Cutaneous Medicine and Surgery
Translating Pharmacokinetics and Pharmacodynamics into Clinical Decision-Making: A Practical Guide to the Use of Risperidone ISM® in Schizophrenia
2026 · Marco Solmi, Olivier Corbeil, et al. · Journal of Clinical Medicine
Canadian Treat-to-Target Practice Survey of Real-World Interventions and Strategies in Psoriasis (CAN TARGET PSORIASIS)
2026 · Jensen Yeung, Parbeer Grewal, et al. · Dermatology and Therapy
PDF
Works count: 38
Citation count: 651
H-index: 9
I10-index: 9
Year
Topic
Type